Figure 1.

Activation of CAR3 attenuates myasthenia in EAMG mice. Female C57BL/6 mice (6- to 8-wk old) were immunized s.c. with Torpedo californica chrn in complete Freund's adjuvant, and were boosted 4 wk later. After 4 more wk, the mice were anesthesized with sodium pentobarbital, fixed and connected to the electrodes of an electromyography machine. Compound muscle action potential in response to repetitive stimulation of the nerve at 3-Hz was recorded (A), and evoked action potential decrements were displayed (B). (C) Blood was collected from mice tail veins and serum was prepared and subjected to ELISA assay for serum anti-CHRN. (D) Paw grip endurance of EAMG mice with or without treatment with AP as per the protocol in (E). (E) Schematic plan of treatment for the mice. EAMG mice were established as mentioned in (A), other than 1-(2-aminoethyl) piperazine (AP, 2 μg/ml) was given in the drinking water from the second immunization (boost). (F) Clinical score of EAMG mice with or without treatment with AP. The images shown are representative of 3 independent experiments. Data are mean ± SEM of 3 independent experiments (B, C, and E), *p < 0.05.